With global recalls of heart burn med Zantac ongoing, the FDA is hoping to restore consumer confidence. Worried about higher-than-recommended levels of a possible carcinogen in the pills? They’re no more dangerous than a grilled ribeye, the agency said Monday. More: FDA: Zantac carcinogens
read moreIndia’s Zydus group began steps to fix its perpetually troubled sterile manufacturing plant in Moraiya as soon as an FDA inspector uncovered manufacturing issues this spring. Its efforts failed to do the job. More: Zydus Cadila injectables plant slapped with FDA warning letter over contamination
read moreSince Allergan’s Namenda approval in late 2003, the world hasn’t seen a new Alzheimer’s drug for 17 years. That drought was broken Saturday, not by a Western biopharma bigwig with a U.S. approval, but a little-known Chinese firm with a
read moreWhen Sanofi bought Genzyme in 2011, Lemtrada was only a promising multiple sclerosis drug candidate, so the French drugmaker promised the biotech’s shareholders future payments if the med hit particular goals. Years later, those investors claimed Sanofi dragged its feet
read moreJohnson & Johnson scored a one-of-a-kind win for SGLT2 med Invokana in September with an FDA approval to treat kidney disease. Now, as a newcomer to the field, J&J is seeking an experienced hand to help sell its flagging med.
read moreThe UK CBD market is worth £300m currently, and its double-digit growth each year has led to market value expectations of almost £1bn by 2025. More: Trade association launched to ‘drive change’ for CBD regulation Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals